Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking
Related MSFT
What's Yahoo Stock Worth?
Kyocera, Microsoft Expand Technology Sharing Agreement
Microsoft's Exit Out Of Display Advertising: A Win For Shareholders (Seeking Alpha)

Analysts at Goldman Sachs downgraded Heartware International (NASDAQ: HTWR) from “neutral” to “sell.” The target price for Heartware International has been lowered from $94 to $73. Heartware's shares closed at $81.26 on Friday.

Analysts at Deutsche Bank downgraded Microsoft (NASDAQ: MSFT) from “buy” to “hold.” The target price for Microsoft is set to $42. Microsoft's shares closed at $39.21 on Friday.

Morgan Stanley downgraded Mindray Medical International (NYSE: MR) from “overweight” to “equal-weight.” The target price for Mindray Medical has been lowered from $44 to $37. Mindray Medical's shares closed at $33.08 on Friday.

Analysts at Credit Suisse downgraded Enbridge (NYSE: ENB) from “outperform” to “neutral.” Enbridge's shares closed at $46.60 on Friday.

Latest Ratings for HTWR

DateFirmActionFromTo
May 2015JP MorganMaintainsOverweight
May 2015BarclaysMaintainsOverweight
Apr 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (HTWR + ENB)

Around the Web, We're Loving...

Get Benzinga's Newsletters